Skip to main content

Table 3 EGFR tyrosine kinase inhibitors or mono-clonal antibodies combined with radiotherapy

From: EGFR inhibition in non-small cell lung cancer: current evidence and future directions

Study Study scheme Stage #Pts RT Dose (Gy) ORR Median PFS Median OS
TKI
Okamoto et al [55] Gefitinib x 14 days, then given concurrently with RT III 9 60 Gy 4 pts who completed with PR   2 pts with EGFR mutations lived >5 yrs.
Choong et al [56] Erlotinib + Cisplatin + Etoposide + RT then docetaxel x 3 cycles vs. Carboplatin + Paclitaxel , then Erlotinib + Carboplatin + Paclitaxel + RT III 17 vs. 17 66 Gy 65% vs. 59%, p = ns 13% vs. 15% at 3 yrs, p = 0.9168 11 mo vs. 15 mo, p = 0.8979
Rothschild et al [57] Erlotinib + RT or Erlotinib + Cisplatin + RT III 14 63 Gy 21.4% 6.0 mo 12.7 mo
Wang et al [58] Gefitinib or Erlotinib + RT III/IV 26 70 Gy 96% 10.2 mo 21.8 mo
Center et al [59] Gefitinib + Docetaxel + RT III 16 70 Gy   7.1 mo 21.0 mo
Stinchcombe et al [60] Carboplatin + Irinotecan + Taxol followed by Carboplatin/Taxol + Gefitinib + RT III 23 74 Gy 24% 9 mo 16 mo
Ready et al [61] Carboplatin/Taxol x 2 cycles ± Gefitinib then Gefinitib + RT vs. Carboplatin/Taxol + Gefitinib + RT; both groups are given Gefitinib after RT if w/o severe radiation toxicity. III 21 vs. 39 66 Gy 52.40% vs. 81.60%, p = 0.034 13.4 mo vs. 9.2 mo 19.0 mo vs. 13.0 mo
Chang et al [62] Upfront TKI, followed by TKI + multitarget IMRT with helical tomotherapy IIIB-IV 25 40-50 Gy in 16–20 daily fractions. 84% 16 mo Not reached, 3 yr OS 62.5%
Komaki et al [63] Carboplatin + Paclitaxel on Monday, followed by Erlotinib for the rest of the week combined with RT; Consolidative Carboplatin + Paclitaxel x 2 cycles were then given III 46 63 Gy/ 35 daily fractions 80% 14.5 mo 34.1 mo
Cetuximab or Nimotuzumab
Hughes et al [66] Platinum based chemotherapy followed by Cetuximab + RT III-IV 12 64 Gy 70%   
Choi et al [67] Weekly Nimotuzumab + RT, then q2 weeks till progression IIB-IV 15 30 or 36 Gy in 3 Gy fractions 46.70% 5.4 mo 9.8 mo
Bebb et al [68] Weekly Nimotuzumab + RT, then q2 weeks till progression III-IV 18 30 or 36 Gy in 3 Gy fractions 66% 4 mo 15 mo
Govindan et al [69] Carboplatin + Pemetrexed + RT vs. Carboplatin + Pemetrexed + Cetuximab + RT III 48 vs. 53 70 Gy 77% vs. 72%, p = ns 12.6 mo vs. 12.3 mo, p = ns 21.2 mo vs. 25.2 mo, p = ns
Jensen et al [70] Cetuximab + RT followed by maintemance Cetuximab III 30 66 Gy   8.5 mo 19.6 mo
Hallqvist et al [71] Cisplatin + Docetaxel followed by Cetuximab + RT III 75 68 Gy 23.5%   17 mo
Blumenschein et al [72] Carboplatin + Taxol + Cetuximab + RT followed Carboplatin + Taxol + Cetuximab III 87 63 Gy 62% 12 mo 22.7 mo